Lomustine and Temozolomide in Combination with Radiotherapy New First-Line Treatment Option for Patients with MGMT Promoter methylated Glioblastoma

被引：0
|
作者：
Seidel, Clemens [1 ]
Kortmann, Rolf-Dieter [1 ]
机构：
[1] Univ Klin Radioonkol & Strahlentherapie, Stephanstr 9a, D-04103 Leipzig, Germany
来源：
STRAHLENTHERAPIE UND ONKOLOGIE | 2019年 / 195卷 / 09期
关键词：
NEWLY-DIAGNOSED GLIOBLASTOMA; BEVACIZUMAB; TRIAL;
D O I：
10.1007/s00066-019-01487-w
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：855 / 856
页数：2
相关论文
共 50 条
  • [21] MGMT promoter methylation status in metastatic melanoma patients receiving first-line temozolomide plus bevacizumab (SAKK 50/07).
    Ochsenbein, A. F.
    Schrami, P.
    Mihic, D.
    Simcock, M.
    Dummer, R.
    Michielin, O.
    Seifert, B.
    Schlaeppi, M. R.
    Moch, H.
    von Moos, R.
    JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)
  • [22] Superiority of temozolomide over radiotherapy for elderly patients with RTK II methylation class, MGMT promoter methylated malignant astrocytoma
    Wick, Antje
    Kessler, Tobias
    Platten, Michael
    Meisner, Christoph
    Bamberg, Michael
    Herrlinger, Ulrich
    Felsberg, Joerg
    Weyerbrock, Astrid
    Papsdorf, Kirsten
    Steinbach, Joachim P.
    Sabel, Michael
    Vesper, Jan
    Debus, Juergen
    Meixensberger, Juergen
    Ketter, Ralf
    Hertler, Caroline
    Mayer-Steinacker, Regine
    Weisang, Sarah
    Boelting, Hanna
    Reuss, David
    Reifenberger, Guido
    Sahm, Felix
    von Deimling, Andreas
    Weller, Michael
    Wick, Wolfgang
    NEURO-ONCOLOGY, 2020, 22 (08) : 1162 - 1172
  • [23] First-line bevacizumab contributes to survival improvement in glioblastoma patients complementary to temozolomide
    Nobuhiro Hata
    Masahiro Mizoguchi
    Daisuke Kuga
    Ryusuke Hatae
    Yojiro Akagi
    Yuhei Sangatsuda
    Takeo Amemiya
    Yuhei Michiwaki
    Yutaka Fujioka
    Kosuke Takigawa
    Satoshi O. Suzuki
    Tadamasa Yoshitake
    Osamu Togao
    Akio Hiwatashi
    Koji Yoshimoto
    Koji Iihara
    Journal of Neuro-Oncology, 2020, 146 : 451 - 458
  • [24] First-line bevacizumab contributes to survival improvement in glioblastoma patients complementary to temozolomide
    Hata, Nobuhiro
    Mizoguchi, Masahiro
    Kuga, Daisuke
    Hatae, Ryusuke
    Akagi, Yojiro
    Sangatsuda, Yuhei
    Amemiya, Takeo
    Michiwaki, Yuhei
    Fujioka, Yutaka
    Takigawa, Kosuke
    Suzuki, Satoshi O.
    Yoshitake, Tadamasa
    Togao, Osamu
    Hiwatashi, Akio
    Yoshimoto, Koji
    Iihara, Koji
    JOURNAL OF NEURO-ONCOLOGY, 2020, 146 (03) : 451 - 458
  • [25] MGMT promoter methylation status and MGMT and CD133 immunohistochemical expression as prognostic markers in glioblastoma patients treated with temozolomide plus radiotherapy
    Consolación Melguizo
    Jose Prados
    Beatriz González
    Raul Ortiz
    Angel Concha
    Pablo Juan Alvarez
    Roberto Madeddu
    Gloria Perazzoli
    Jaime Antonio Oliver
    Rodrigo López
    Fernando Rodríguez-Serrano
    Antonia Aránega
    Journal of Translational Medicine, 10
  • [26] MGMT promoter methylation status and MGMT and CD133 immunohistochemical expression as prognostic markers in glioblastoma patients treated with temozolomide plus radiotherapy
    Melguizo, Consolacion
    Prados, Jose
    Gonzalez, Beatriz
    Ortiz, Raul
    Concha, Angel
    Juan Alvarez, Pablo
    Madeddu, Roberto
    Perazzoli, Gloria
    Antonio Oliver, Jaime
    Lopez, Rodrigo
    Rodriguez-Serrano, Fernando
    Aranega, Antonia
    JOURNAL OF TRANSLATIONAL MEDICINE, 2012, 10
  • [27] MGMT promoter methylation status and MGMT and CD133 immunohistochemical expression as prognostic markers in glioblastoma patients treated with temozolomide plus radiotherapy
    Gonzalez-Astorga, B.
    Luque, R.
    Castellon, V.
    Gonzalez, E.
    Sanchez, C.
    Soberino, J.
    Gonzalez, C.
    Ruiz, J.
    Zurita, M.
    Delgado, J. R.
    EUROPEAN JOURNAL OF CANCER, 2013, 49 : S794 - S794
  • [28] Phase II Trial of Bevacizumab in Combination With Temozolomide as First-Line Treatment in Patients With Metastatic Uveal Melanoma
    Piperno-Neumann, Sophie
    Diallo, Alhassane
    Etienne-Grimaldi, Marie-Christine
    Bidard, Francois-Clement
    Rodrigues, Manuel
    Plancher, Corine
    Mariani, Pascale
    Cassoux, Nathalie
    Decaudin, Didier
    Asselain, Bernard
    Servois, Vincent
    ONCOLOGIST, 2016, 21 (03): : 281 - 282
  • [29] Bevacizumab, irinotecan, and radiotherapy versus standard temozolomide and radiotherapy in newly diagnosed, MGMT-non-methylated glioblastoma patients: First results from the randomized multicenter GLARIUS trial.
    Herrlinger, Ulrich
    Schaefer, Niklas
    Steinbach, Joachim Peter
    Weyerbrock, Astrid
    Hau, Peter
    Goldbrunner, Roland
    Friedrich, Franziska
    Stockhammer, Florian
    Ringel, Florian
    Braun, Christian
    Kohnen, Ralf
    Leutgeb, Barbara
    Belka, Claus
    Urbach, Horst
    Stummer, Walter
    Glas, Martin
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)
  • [30] Combination chemotherapy versus temozolomide (TMZ) for patients with MGMT methylated (m-MGMT) glioblastoma (GBM): Results of cellworks omics biosimulation-MyCare-015.
    Castro, Michael
    Mundkur, Nirjhar
    Pampana, Anusha
    Alam, Aftab
    Alam, Aktar
    Parashar, Rajan
    Rajagopalan, Swaminathan
    Lala, Deepak Anil
    Roy, Kunal Ghosh Ghosh
    Basu, Sayani
    Prakash, Annapoorna
    Nair, Prashant
    Christie, Jim
    Joseph, Vishwas
    Agarwal, Ashish
    Poornachandra, G.
    Behura, Liptimayee
    Kulkarni, Shruthi
    Choudhary, Nikita Ray
    Kapoor, Shweta
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
12345